Investors Purchase Large Volume of Call Options on ImmunityBio (NASDAQ:IBRX)

ImmunityBio, Inc. (NASDAQ:IBRX) saw unusually large options trading on Thursday. Traders acquired 8,015 call options on the company. This is an increase of 36% compared to the typical volume of 5,894 call options.

Institutional Investors Weigh In On ImmunityBio

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. State Street Corp grew its holdings in ImmunityBio by 10.1% during the third quarter. State Street Corp now owns 8,654,460 shares of the company’s stock valued at $32,195,000 after purchasing an additional 790,408 shares during the last quarter. Barclays PLC grew its stake in ImmunityBio by 127.4% in the 3rd quarter. Barclays PLC now owns 361,036 shares of the company’s stock valued at $1,344,000 after buying an additional 202,248 shares during the last quarter. B. Riley Wealth Advisors Inc. bought a new position in ImmunityBio in the 2nd quarter worth $515,000. GSA Capital Partners LLP lifted its position in ImmunityBio by 290.3% during the 3rd quarter. GSA Capital Partners LLP now owns 107,985 shares of the company’s stock worth $402,000 after acquiring an additional 80,318 shares during the last quarter. Finally, Private Advisor Group LLC boosted its holdings in ImmunityBio by 727.7% during the second quarter. Private Advisor Group LLC now owns 86,907 shares of the company’s stock valued at $549,000 after acquiring an additional 76,407 shares during the period. 8.58% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. D. Boral Capital reiterated a “buy” rating and set a $30.00 price target on shares of ImmunityBio in a report on Thursday. EF Hutton Acquisition Co. I upgraded shares of ImmunityBio to a “strong-buy” rating in a research note on Wednesday, October 23rd. Finally, BTIG Research started coverage on shares of ImmunityBio in a research note on Friday, January 10th. They set a “buy” rating and a $6.00 price target on the stock.

ImmunityBio Price Performance

Shares of NASDAQ:IBRX opened at $3.04 on Friday. The stock has a market capitalization of $2.12 billion, a P/E ratio of -3.30 and a beta of 0.86. The business has a 50-day moving average of $3.78 and a two-hundred day moving average of $4.26. ImmunityBio has a fifty-two week low of $2.28 and a fifty-two week high of $10.53.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.